View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 22, 2020

Atomwise leverages AI to explore broad-spectrum Covid-19 drugs

Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.

Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

While drug repurposing may enable a quicker response to the current outbreak, its long-term use may be limited due to mutations and evolution of the virus, noted the company.

Atomwise and its collaborators will leverage the company’s predictive models and artificial intelligence (AI) technology to potentially increase the ‘probability of success for future therapies’.

Last September, Atomwise signed four deals for AI-based drug discovery.

Each collaborative project focuses on the development of drug candidates that demonstrate broad-spectrum properties, in turn offering potential long-term benefit for coronavirus outbreaks in the future.

The 15 research projects cover various approaches, including various mechanisms of action, a combination of viral and human/host target proteins and targeting conserved protein regions identifiable even in mutated strains.

Most of the projects fall under Atomwise’s Artificial Intelligence Molecular Screen (AIMS) programme, intended to help researchers speed-up the translation of their research into treatments.

In addition, to support each partnership, Atomwise scientists will use its AI screening technology, AtomNet, to predict the binding of numerous small molecules to a protein of interest discovered by the academic researcher as a potential Covid-19 target.

Speaking of the development, Atomwise AIMS vice-president and head Dr Stacie Calad-Thomson said: “Atomwise’s AI screening technology is used to predict the binding of more than 10 million small molecules to a protein of interest, and far exceeds what could be accomplished through traditional laboratory screening methods.

“With Atomwise’s AIMS Awards programme, our hope is to democratise access to AI during the early stages of preclinical drug development and enable academics to contribute to the pandemic response who might not have the opportunity otherwise.”

The aim of the collaborations is to address the current pandemic, as well as mutations, recurrences or other coronavirus strains in the future.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU